FDA seeks comments on ways to facilitate appropriate opioid prescribing
The Food and Drug Administration seeks stakeholder input on how it might use Risk Evaluation and Mitigation Strategies to facilitate appropriate prescribing of opioid pain relievers. For example, the agency’s Opioid Policy Steering Committee is considering using REMS to require sponsors to ensure that opioid analgesic prescriptions exceeding a certain amount document medical necessity and/or leverage a nationwide prescription history database to prevent misuse or abuse, the FDA notice states. The agency will hold a Jan. 30 public hearing on the issue, with comments accepted through March 16.
Related News Articles
Headline
The Department of Health and Human Services June 23 announced an initiative coordinated with multiple health insurance companies to streamline prior…
Headline
Ochsner Health's Stephen Saenz, sepsis program manager, and Teresa Arrington, director of robust process improvement for quality and patient safety, reveal how…
Headline
The AHA this week is launching a new ad urging Congress to protect access to hospital care as it considers legislation that could have far-ranging negative…
Headline
The Centers for Medicare & Medicaid Services June 20 announced it is finalizing its 2025 Marketplace Integrity and Affordability final rule. The rule…
Headline
The U.S. District Court for the Northern District of Iowa June 18 vacated components of the Centers for Medicare & Medicaid Services’ minimum nurse…
Headline
A new video in the AHA’s series “Medicaid: Real Lives, Real Care” features insight from Leah Blackwell, R.N., vice president and chief nursing officer at…